A Phase 4 interventional study of Clopidogrel and Aspirin in Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia and Staphylococcus Aureus Bloodstream Infection, sponsored by Todd C. Lee MD MPH FIDSA. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Todd C. Lee MD MPH FIDSA · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events. We will randomize patients to continue their aspirin or change clopidogrel which is also approved for secondary prevention.
Unlike aspirin, clopidogrel may have activity against S. aureus. We wish to determine if changing to clopidogrel will improve outcomes in S. aureus bacteremia in people who otherwise would have a reason to be taking it.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119).
If positive, this study will support a Phase 3 RCT in people who do not currently have an indication for clopidogrel.
173 studies on the registry are indexed under Endocarditis; 56 are open to participants now.
This study's planned enrollment of 300 is above the median of 92 across 86 interventional studies indexed under Endocarditis.
Browse Endocarditis studies →Todd C. Lee MD MPH FIDSA is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant must meet all inclusion and exclusion criteria for the SNAP
Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion Criteria:
Exclusion Criteria:
Patients will have their aspirin discontinued and start clopidogrel.
Drug: Clopidogrel
Patients will continue their existing aspirin
Drug: Aspirin
Patients will change from aspirin to clopidogrel (without loading dose)
Patients will continue their existing aspirin.
Desirability of Outcome Ranking (DOOR)
Desirability of Outcome Ranking (DOOR) - an ordinal outcome with 5 levels defined: Rank 1 - Alive without complication Rank 2 - Alive with 1 complication Rank 3 - Alive with 2 complications Rank 4 - Alive with 3 complications Rank 5 - Dead Complications include: 1. Clinical failure: Absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated. 2. Infectious Complications: Including new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures 3. Serious adverse drug event (Common Terminology Criteria class 4) due to study drug OR adverse drug event (classes 1-3) leading to discontinuation of the study drug * Ties broken by length of stay for index hospitalization
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinical Failure
Defined as the absence of resolution of clinical signs and symptoms of S. aureus bacteremia such that no additional antibiotic therapy is required or anticipated for its treatment.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Serious Adverse Event or Adverse Event Leading to Discontinuation
Defined as a serious adverse drug event (Common Terminology Criteria for Adverse Events (CTCAE) class 4) presumed due to study drug OR adverse drug event (CTCAE classes 1-3) leading to discontinuation of the study drug
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
All cause mortality
Death from any cause
Time frame: At Days 14, 28, 42 and 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Infectious Complications
Defined as new endocarditis; new evidence of other deep metastatic foci (e.g., osteomyelitis or deep abscess); relapse of bacteremia after a patient has sterilized their initial blood cultures; readmission for subsequent care of S. aureus bacteremia; need for unplanned source control procedures. New implies that the complication was not suspected at enrollment and is not a function of delay to diagnostic testing.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant major bleeding
This will be defined according to the criteria of the International Society on Thrombosis and Haemostasis as one or more of the following: fatal bleeding; symptomatic bleeding in a critical area or organ (including hemorrhagic stroke); bleeding that causes a fall in hemoglobin level of ≥20 g/L; or bleeding that requires a transfusion of 2 or more units of whole blood or red cells. For bleeds into non-critical areas, we will also record the site of bleeding.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant venous thromboembolic events
This will be defined as an acute objectively confirmed deep vein thrombosis (upper extremity, lower extremity, other such as portal vein, cerebral vein, splanchnic vein) and/or segment or proximal pulmonary embolism, which is symptomatic and/or necessitates specific treatment. Below knee DVT and superficial thrombophlebitis are not included. Pulmonary embolism needs to be, segmental or proximal. Subsegmental pulmonary embolisms are not included as they have poor interrater reliability and may represent artefact in up to 50% of cases.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant stroke
Stroke is defined as the acute onset of focal neurological dysfunction caused by brain, spinal cord, or retinal vascular injury because of infarction (ischemia). Ideally, at least one of the following should be present to confirm the diagnosis of stroke: confirmation by neurology, stroke specialist, or neurosurgical specialist, brain imaging (e.g., CT scan, MRI scan, or cerebral vessel angiography compatible with acute ischemia). If the acute focal signs represent a worsening of a previous deficit, these signs must persist for more than 24 hours and be accompanied by an appropriate new MRI or CT scan finding. In the absence of neuroimaging, a staff neurologist consult which makes the diagnosis of stroke will be considered.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant acute myocardial infarction
Patients with S. aureus bacteremia often have substantial physiological stresses which can be associated with rises in cardiac troponin (demand ischemia). For the purposes of this outcome, acute myocardial infarction is captured as a type 1 myocardial infarction: detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia. For the purposes of this pragmatic trial, such a myocardial infarction will be inferred from the opinions of the staff cardiologist, intensivist, or general internal medicine specialist. The peak troponin value will be recorded, and a redacted copy of the relevant consultant's note and ECGs will be uploaded for audit.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Clinically relevant arterial thromboembolic event
Clinical history compatible with sudden worsening of end organ or limb perfusion and confirmation by imaging (e.g., CT angiography, arterial doppler) or need for urgent surgery or thrombolysis.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Length of stay
Amongst survivors, the length of inpatient stay for the index hospitalization.
Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)
Plan to share: Yes — All IPD that underlie results in the primary publication.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Beginning 1 year after publication with no end date
Access criteria: Post publication access to the trial dataset and statistical analysis may be made available upon reasonable request and with institutional data sharing agreements with the trial sponsor.
Data sharing details ↗ · cdn.prod.website-files.com
Started Feb 2026 (actual). Primary completion is estimated for Jan 2030, 47 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel
Todd C. Lee MD MPH FIDSA